Summary
Background. Diabetes mellitus or impaired glucose tolerance occurs in up to 80% of patients with pancreatic cancer at the time of cancer diagnosis. It has been reported that plasma amylin (islet amyloid polypeptide [IAPP]) levels are elevated in all patients with pancreatic cancer who are diabetic, and even moderately elevated in pancreatic cancer patients with normal glucose tolerance.
Aim. To determine the specificity of elevated amylin levels for pancreatic cancer.
Methods. Plasma amylin levels were determined in 168 patients with one or more of the following medical conditions: benign and malignant biliary obstruction, pancreatic cancer, chronic pancreatitis, acute pancreatitis, other gastrointestinal (GI) malignancies, and newly diagnosed type II diabetes.
Results. Elevated levels of plasma amylin were detected in several disorders other than pancreatic cancer—particularly chronic pancreatitis, other GI malignancies, and biliary obstruction from benign causes. No statistical differences in amylin levels were detected for any of the tested medical conditions when compared to pancreatic adenocarcinoma.
Conclusion. These results suggest that elevated plasma amylin is not specific for pancreatic cancer, thereby limiting its role as a tumor marker. Further studies are needed to determine whether amylin, if used in conjunction with other biological markers, could be useful for the diagnosis of pancreatic cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer Statistics, 2001. CA Cancer J Clin 2001;51:15–36.
Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995;221:721–731.
Brand RE, Matamoros A. Imaging techniques in the evaluation of adenocarcinoma of the pancreas. Dig Dis 1998;16:242–252.
Schwarz SS, Zeidler A, Moossa AR, et al. A prospective study of glucose tolerance, insulin, C-peptide and glucagon responses in patients with pancreatic carcinoma. Dig Dis Sci 1978;23:1107–1114.
Permert J, Ihse I, Jorfeldt L, et al. Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg 1993;159:101–107.
Permert J, Larsson J, Westermark GT, et al. Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N Eng J Med 1994;330:313–318.
Bretherton-Watt D, Ghatei MA, Bloom SE, et al. Islet amyloid polypeptide-like immunoreactivity in human tissue and endocrine tumors. J Clin Endocrinol Metab 1993;76:1072–1074.
Butler PC, Chou J, Carter WB, et al. Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes 1990;39:752–756.
Sanke T, Hanabusa T, Nakano Y, et al. Plasma islet amyloid polypeptide (amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1991;34:129–132.
Hartter E, Svoboda T, Ludvik B, et al. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin. Diabetologia 1991;34:52–54.
Eriksson J, Nakazato M, Miyazato M, et al. Islet amyloid polypeptide plasma concentrations in individuals at increased risk of developing type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992;35:291–293.
Phillips AR, Abu-Zidan FM, Bonham MJ, et al. Amylin and severe acute pancreatitis. Pancreas 2000;20:105–106.
Chari S, Klee GG, Miller LJ, et al. Sensitivity and specificity of CA19-9 and islet amyloid polypeptide (IAPP) for symptomatic pancreatic cancer (PC). Abstract for American Pancreatic Association Mtg 1998. Gastroenterology 2001;121:640–645.
Niederau C, Grendell JH. Diagnosis of pancreatic carcinoma. Pancreas 1992;7:66–86.
Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990;85:350–355.
Kondo H, Sugano K, Fukayama N, et al. Detection of point mutations in the K-ras oncogene at codon 12 in pure pancreatic juice for diagnosis of pancreatic carcinoma. Cancer 1994;73:1589–1594.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brand, R.E., Ding, XZ., Young, C.M. et al. The specificity of amylin for the diagnosis of pancreatic adenocarcinoma. Int J Gastrointest Canc 31, 123–128 (2002). https://doi.org/10.1385/IJGC:31:1-3:123
Issue Date:
DOI: https://doi.org/10.1385/IJGC:31:1-3:123